SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study.

Bennett, A; Pollock, L; Bar-Zeev, N; Lewnard, JA; Jere, KC; Lopman, B; Iturriza-Gomara, M; Pitzer, VE; Cunliffe, NA (2021) Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study. Lancet Infect Dis, 21 (5). pp. 731-740. ISSN 1474-4457 https://doi.org/10.1016/S1473-3099(20)30597-1
SGUL Authors: Bennett, Aisleen

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (628kB) | Preview

Abstract

BACKGROUND: Rotavirus vaccine effectiveness is reduced among children in low-income countries. Indirect (transmission-mediated) effects of rotavirus vaccine might contribute to the total population effect of vaccination. We aimed to examine risk factors for transmission of rotavirus to household contacts in Blantyre, Malawi, and estimated the effectiveness of rotavirus vaccine in preventing transmission of infection to household contacts. METHODS: In this prospective household cohort study, we recruited children born after Sept 17, 2012, and aged at least 6 weeks (vaccine-eligible children) with acute rotavirus gastroenteritis and their household contacts, in four government health facilities in Blantyre, Malawi. Clinical data, a bulk stool sample, and 1-2 mL of serum were collected from case children at presentation. Clinical data and stool samples were also prospectively collected from household contacts over 14 days from presentation. A single stool sample was collected from control households containing asymptomatic children who were frequency age-matched to case children. Samples were tested for rotavirus using semi-quantitative real-time PCR and for anti-rotavirus IgA using a semi-quantitative sandwich ELISA. Risk factors for household transmission of rotavirus infection and clinical disease, including disease severity and faecal shedding density, were identified using mixed effects logistic regression. Vaccine effectiveness against transmission was estimated as 1 minus the ratio of secondary attack rates in vaccinated and counterfactual unvaccinated populations, using vaccine effectiveness estimates from the associated diarrhoeal surveillance platform to estimate the counterfactual secondary attack rate without vaccination. FINDINGS: Between Feb 16, 2015, and Nov 11, 2016, we recruited 196 case households (705 members) and 55 control households (153 members). Household secondary attack rate for rotavirus infection was high (434 [65%] of 665 individuals) and secondary attack rate for clinical disease was much lower (37 [5%] of 698). Asymptomatic infection in control households was common (40 [28%] of 144). Increasing disease severity in an index child (as measured by Vesikari score) was associated with increased risk of transmission of infection (odds ratio 1·17 [95% CI 1·06-1·30) and disease (1·28 [1·08-1·52]) to household contacts. Estimated vaccine effectiveness against transmission was 39% (95% CI 16-57). INTERPRETATION: Rotavirus vaccine has the potential to substantially reduce household rotavirus transmission. This finding should be considered in clinical and health economic assessments of vaccine effectiveness. FUNDING: Wellcome Trust, US National Institutes of Health, and US National Institute of Allergy and Infectious Diseases.

Item Type: Article
Additional Information: © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Keywords: 1103 Clinical Sciences, 1108 Medical Microbiology, Microbiology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Lancet Infect Dis
ISSN: 1474-4457
Language: eng
Dates:
DateEvent
May 2021Published
24 December 2020Published Online
18 June 2020Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
102466/Z/13/AWellcome Trusthttp://dx.doi.org/10.13039/100004440
102464/Z/13/AWellcome Trusthttp://dx.doi.org/10.13039/100004440
091909/Z/10/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
101113/Z/13/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
R01-AI112970National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
201945/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 33357507
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/112758
Publisher's version: https://doi.org/10.1016/S1473-3099(20)30597-1

Actions (login required)

Edit Item Edit Item